Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0RHSBY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Brentuximab-8
|
|||||
| Synonyms |
Brentuximab-8 DAR8
Click to Show/Hide
|
|||||
| Organization |
Tubulis GmbH; Bristol Myers Squibb Co.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 3 Indication(s)
Acute promyelocytic leukemia [ICD11:2A60]
Clinical candidate
Cutaneous mesenchymal large cell lymphoma [ICD11:2B00]
Clinical candidate
Hodgkin lymphoma [ICD11:2B30]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Brentuximab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 8 (TNFRSF8)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Alkyl phosphoramide-PEG24-Val-Cit-PAB
|
Linker Info | ||||
| Conjugate Type |
P5 ADC technology, linker conjugating via alkyl phosphoramidites and antibody cysteine sulfhydryl groups.
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.60 pM | High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-8 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | ALK-positive anaplastic large cell lymphoma | Karpas-299 cells | CVCL_1324 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.50 pM | High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-8 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Hodgkin lymphoma | L-540 cells | CVCL_1362 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.20 pM | High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-8 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Anaplastic large cell lymphoma | SU-DHL-1 cells | CVCL_0538 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.10 pM | High CD30 expression (CD30+++) | ||
| Method Description |
The inhibitory activity of Brentuximab-8 against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.